Search

Neuromod Devices’ €30m funding powers Lenire expansion

Neuromod Devices, the global technology business behind scientifically proven tinnitus treatment technology, Lenire, closed €30m funding to expand availability of the groundbreaking tinnitus intervention.

Neuromod closes €10 million financing to accelerate commercialisation

Neuromod, an Irish medical device company specialising in tinnitus, has closed a €10 million equity financing deal in a Series B fundraising expansion to expand the availability of tinnitus treatment device, Lenire. Financing was oversubscribed and led by existing investors...

Neuromod launches Ótologie specialist tinnitus care service

Medical device company, Neuromod Devices Ltd, has launched a specialist tinnitus care service, Ótologie.

Neuromod launches Lenire tinnitus treatment device to tinnitus sufferers in the UK

Neuromod Devices has launched its Lenire tinnitus treatment device in the United Kingdom, where it is estimated that seven million people suffer from tinnitus.

Neuromod establishes global leadership team following launch of Lenire in Spain

Neuromod Devices has announced the formation of a global commercial leadership team to further commercialise its Lenire tinnitus treatment device through key partnerships.

Neuromod advances multiple regulatory approvals to expedite Lenire’s global availability

Neuromod, the medical technology company that created the Lenire® tinnitus treatment device, has announced approval to the Medical Device Single Audit Program (MDSAP) and EU Medical Device Regulation (MDR) certification. Neuromod’s MDSAP certification follows a comprehensive audit verifying compliance with...

Neuromod establishes US subsidiary and appoints Eric Timm as US Chief Executive Officer

Neuromod Devices Ltd, the Irish medical device company which specialises in neuromodulation technologies, has announced the establishment of Neuromod USA Inc., a subsidiary headquartered in Oak Brook, Illinois.

Neuromod publishes results of second large-scale clinical trial for tinnitus, shows greater improvement of symptoms

Neuromod Devices, the medical device company specialising in tinnitus, has published the results of its TENT-A2 (Treatment Evaluation of Neuromodulation for Tinnitus – Stage A2) clinical trial in the scientific journal, Nature – Scientific Reports in a paper titled ‘Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial’.

Neuromod expands availability of Lenire tinnitus treatment device in Europe with 19 new clinical partnerships

Neuromod Devices, the technology company that specialises in medical devices for tinnitus treatment, has announced 19 new clinical partnerships to expand the availability of the Lenire tinnitus treatment device in Europe. This latest expansion will significantly increase the number of...

Lenire®, the tinnitus treatment device, now available in Norway

Neuromod Devices Ltd., has reached an agreement with HØR AS, Norway’s largest private provider of hearing and tinnitus care, to make its Lenire tinnitus treatment device available in Norway.

FDA grants Lenire tinnitus treatment device De Novo approval

Neuromod Devices Ltd. is proud to announce that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire.

FDA Approved Lenire Expands Number of US Clinics

Neuromod Devices, the medical technology company that developed tinnitus treatment device, Lenire, has partnered with an additional 24 new US clinics to address the significant demand for the FDA Approved tinnitus treatment device.